Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppression with ATG, Rituximab, Sirolimus, and MMF in Mismatched HCT
NCT01582048Phase 2Terminated
- Start
- Apr 2012
- Primary completion
- Aug 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit, rituximab, sirolimus, mycophenolate mofetil in graft-versus-host disease (GVHD). Started Apr 2012; status: terminated.
02
Drugs
antithymocyte globulin rabbitrituximabsirolimusmycophenolate mofetil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01582048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582048.